Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies
    Meeting Abstract

    Tsurutani, J.; Doi, T.; Iwata, H.; Takahashi, S.; Modi, S.; Tamura, K.; Shitara, K.; Taniguchi, H.; Taira, S.; Li, B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene recurrence score (RS) assay and other genomic assays for early breast cancer (EBC)
    Meeting Abstract

    Varga, Z.; Sinn, P.; McCullough, D.; Lau, A.; Stöppler, M. C.; Baehner, F. L.; Chao, C.; Seidman, A.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update
    Meeting Abstract

    Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, M. W.; Autio, K.; Infante, J. R.; Patel, M. R.; Papadopoulos, K.; Naing, A.; Gabrail, N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
    Meeting Abstract

    Wainberg, Z. A.; Jalal, S.; Muro, K.; Yoon, H. H.; Garrido, M.; Golan, T.; Doi, T.; Catenacci, D. V.; Geva, R.; Ku, G.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C
    Meeting Abstract

    Rai, R.; Ezeoke, O. M.; McQuade, J. L.; Zimmer, L.; Koo, C.; Park, J. J.; Ardolino, L.; Yip, D.; Goldinger, S.; Cohen, J. V.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Meeting Abstract

    Robert, C.; Larkin, J.; Ascierto, P. A.; Long, G. V.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC)
    Meeting Abstract

    Robson, M.; Ruddy, K. J.; Im, S. A.; Senkus-Konefka, E.; Xu, B.; Domchek, S. M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
    Meeting Abstract

    Rudin, C. M.; Shen, L.; Pietanza, M. C.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
    Meeting Abstract

    Saura, C.; de Azambuja, E.; Hlauschek, D.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Nuciforo, P.; Ballestrero, A.; Fornier, M. N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
    Meeting Abstract

    Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save